SCHEMBL14075988

SCHEMBL14075988

Cc1ccc2c(c1)nc(-c1ccc(N(C)C)cc1)n2C

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.68
KDM4E B2RXH2 7/20 0.68
HSD17B10 Q99714 6/20 0.68
RAB9A P51151 5/20 0.68
MAPT P10636 5/20 0.68
HPGD P15428 5/20 0.68
NPC1 O15118 5/20 0.68
TP53 P04637 4/20 0.68
LMNA P02545 3/20 0.68
SMN1; SMN2 Q16637 3/20 0.68
HTT P42858 3/20 0.68
GFER P55789 3/20 0.68
PKM P14618 2/20 0.68
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA9 Q16790 1/20 0.49
APP P05067 2/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14075990 0.85 ALDH1A1 (0.65) ALDH1A1KDM4EHSD17B10RAB9AMAPT
SCHEMBL14364730 0.85 ALDH1A1 (0.65) ALDH1A1KDM4EHSD17B10RAB9AMAPT
SCHEMBL9755122 0.81 ALDH1A1 (1.00) ALDH1A1KDM4EHSD17B10RAB9AMAPT
SCHEMBL10030014 0.81 NLRP3 (0.61) ALDH1A1KDM4EHSD17B10RAB9AMAPT
SCHEMBL1104834 0.81 NLRP3 (0.65) ALDH1A1KDM4EHSD17B10RAB9AMAPT
SCHEMBL10249140 0.80 MEN1 (0.66) ALDH1A1KDM4EHSD17B10RAB9AMAPT
SCHEMBL15080534 0.79 CA12 (0.49) ALDH1A1KDM4EHSD17B10RAB9AMAPT
SCHEMBL30425393 0.77 CA1 (0.64) ALDH1A1RAB9APKMCA12CA1
SCHEMBL17149164 0.76 HDAC1 (0.49) ALDH1A1KDM4EHSD17B10RAB9AMAPT
SCHEMBL10248879 0.76 CA1 (0.49) ALDH1A1KDM4EHSD17B10RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE44354-E1 Amyloid plaque aggregation inhibitors and diagnostic imaging agents THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2013-07-09 US disclosed
US-RE44338-E1 Amyloid plaque aggregation inhibitors and diagnostic imaging agents THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2013-07-02 US disclosed
US-7425318-B2 Amyloid plaque aggregation inhibitors and diagnostic imaging agents THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2008-09-16 US disclosed
US-20070254889-A1 Compounds and methods useful for rescuing cells from beta-amyloid toxicity and treatment of Alzheimer's disease THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254889-A1 Compounds and methods useful for rescuing cells from beta-amyloid toxicity and treatment of Alzheimer's disease APP, BACE1, IAPP ALDH1A1 1209/4885KDM4E 1627/4885HSD17B10 1585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.